Reto Agosti
Overview
Explore the profile of Reto Agosti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
217
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gantenbein A, Bonvin C, Kamm C, Schankin C, Zecca C, Zieglgansberger D, et al.
J Neurol
. 2024 Jun;
271(8):5402-5410.
PMID: 38871822
Background: There are limited real-world data in Switzerland examining the impact of erenumab, a fully human IgG2 monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) receptor, on migraine-related quality of...
2.
Agosti R, Parzini C, Findling O, Myers P, Petersen J, Ryvlin P, et al.
Pain Ther
. 2023 Feb;
12(2):575-591.
PMID: 36842093
Introduction: There is limited real-world evidence on the burden of migraine among patients with prior preventive treatment failure (PPTF). In the BECOME Swiss subanalysis, we aimed to assess current prevalence...
3.
Gantenbein A, Agosti R, Kamm C, Landmann G, Meier N, Merki-Feld G, et al.
J Headache Pain
. 2022 Dec;
23(1):161.
PMID: 36536271
No abstract available.
4.
Gantenbein A, Agosti R, Kamm C, Landmann G, Meier N, Merki-Feld G, et al.
J Headache Pain
. 2022 Nov;
23(1):142.
PMID: 36401172
Background: The fully human monoclonal antibody erenumab, which targets the calcitonin gene-related peptide (CGRP) receptor, was licensed in Switzerland in July 2018 for the prophylactic treatment of migraine. To complement...
5.
Gantenbein A, Agosti R, Gobbi C, Flugel D, Schankin C, Viceic D, et al.
Cephalalgia
. 2021 May;
41(11-12):1181-1186.
PMID: 34000847
Objective: This study aims to analyse the effect of the discontinuation of anti-calcitonin gene-related peptide antibodies on monthly migraine days after 12 treatment months. Background: Anti-calcitonin gene-related peptide antibodies have...
6.
Huber C, Agosti R, Napflin M, Blozik E
Pharmacoepidemiol Drug Saf
. 2019 Dec;
29(3):279-287.
PMID: 31828875
Purpose: In course of the new migraine drug development on the global market it is important to quantify the current burden of migraine medication. This study aimed to estimate the...
7.
Huber C, Agosti R, Napflin M, Blozik E
J Pain Res
. 2019 Aug;
12:2211-2221.
PMID: 31413619
Purpose: The newly developed calcitonin gene-related peptide (CGRP) antagonists were recently launched on the US and European market, with Switzerland as the second country worldwide. To enable forthcoming comparisons with...
8.
Agosti R
Headache
. 2018 Apr;
58 Suppl 1:17-32.
PMID: 29697152
Migraine is one of the most common diseases worldwide and, importantly, a major cause of disability. This translates into a huge clinical and economic burden to individuals and society. Despite...
9.
Bumb A, Seifert B, Wetzel S, Agosti R
Springerplus
. 2013 Sep;
2:377.
PMID: 24010035
Background: To evaluate if white matter lesions (WML) on MRI can be a potential marker for onabotulinum toxin A (Botox®) treatment success in migraine, given the limited response rate and...
10.
Merki-Feld G, Imthurn B, Seifert B, Merki L, Agosti R, Gantenbein A
Eur J Contracept Reprod Health Care
. 2013 Aug;
18(5):394-400.
PMID: 23927694
Objective: To analyse the effects of a three-month course of progestogen-only contraception with desogestrel 75 μg on disability, headache frequency and headache intensity in migraineurs. Materials And Methods: Migraine disability...